BRIDGEBIO PHARMA INC BBIO
ASignal's systematic analysis rates BBIO as Bearish.
Reflects the latest available analysis · analyzed Oct 31, 2026
The case on BBIO
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (120.4% YoY)
- High gross margin (94.44%) indicating pricing power
- Positive MACD histogram expansion suggesting strengthening momentum
- Price above 20-day and 50-day moving averages
- RSI at 76.50 indicating overbought conditions
- Price trading above upper Bollinger Band suggesting potential pullback
- Negative profit margin (-97.03%) and operating cash flow
- High EV/Revenue (23.12x) and negative EV/EBITDA (-34.88x)
- Negative free cash flow and return on assets
See the full verdict on BBIO
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes BBIO
Most investors never get a second opinion, let alone several. ASignal runs BBIO past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.